Clinical Trial Update: Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the RAD regimen (lenalidomide, doxorubicin, dexamethasone) in newly diagnosed multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Adriamycin (doxorubicin) (doxorubicin)
• DEXAMETHASONE (Dexamethasone)
• Revlimid (lenalidomide) (lenalidomide)

Snippet

Sponsor: Meletios A. Dimopoulos | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED